(Press-News.org) Insilico Medicine (“Insilico”), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that it has received USD 5 million from Menarini Group (“Menarini”) as an additional milestone payment, following the completion of first-in-patient dosing in a Phase 1 study of MEN2501, whose license-out agreement with Menarini was disclosed in January 2025. MEN2501 (previously known as ISM9682) is a highly differentiated small molecule inhibitor of kinesin KIF18A motor protein with potent activity in cancers with chromosome instability.
As part of a strategic collaboration to accelerate the development and delivery of transformative cancer therapies, the asset was subsequently licensed to Stemline Therapeutics, Inc. (“Stemline”), a wholly owned subsidiary of the Menarini Group, with the combined value of the agreements exceeding USD 550 million. Pursuant to the partnership, both parties actively advanced the program transition and subsequent development activities. Following IND approval for this program, Insilico received the first development and regulatory milestone payment of USD 3 million in July 2025.
“The program rapidly advanced into a Phase I clinical trial and successfully completed first patient dosing, fully demonstrating Menarini and Stemline’s exceptional agility and clinical expertise,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “This milestone shows our shared commitment to delivering innovative therapies for cancer treatment. We are proud to further strengthen our partnership and encouraged to see AI-discovered drug candidates reaching such a critical stage, bringing us closer to providing novel treatment options for patients worldwide.”
“Getting the first patient dosed in our MEN2501 Phase 1 study is a meaningful milestone that underscores how quickly promising science can move forward through focused clinical execution,” said Elcin Barker Ergun, CEO of the Menarini Group. “We value our partnership with Insilico as we translate AI-enabled discovery into clinical programs, with the goal of bringing new, transformational treatment options to patients facing aggressive cancers.”
The collaboration between Insilico and Menarini has continued to expand since its inception. Prior to MEN2501, in January 2024, Insilico announced that it entered into an exclusive global license collaboration with Menarini for MEN2312, a novel KAT6 inhibitor for breast cancer and other oncology indications, with the combined value of the agreements exceeding USD 500 million. The MEN2312 program has progressed smoothly into clinical development, and Insilico has received early development milestone payments.
In addition to the collaboration pipelines, Insilico has extensive experience in AI-driven oncology, drug discovery and development. The company has established a robust oncology pipeline that targets multiple cancer indications, leveraging both moderately novel and well-established mechanisms. Among its most promising assets, the potential best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412 are both undergoing global, multicenter Phase I clinical trials.
Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com
END
As we shift toward more sustainable fuels, natural gas and biogas, which mainly contain methane (CH4), have become important sources of energy and raw materials for chemical production. However, these gases also contain impurities that must be removed before use. One major contaminant is carbon dioxide (CO2), which reduces the energy content of the gas and can cause corrosion in pipelines.
One promising method for efficiently separating CO2 from these gases is filtration using graphene membranes containing ...
Thermoelectric conversion devices offer a promising route for sustainable heat-to-energy conversion. They are particularly attractive for recovering energy from waste heat, such as that produced by conventional fossil fuel-based engines, improving their overall energy efficiency. Around 20–50% of the input energy is lost as waste heat in industries. This could be used as source by thermoelectric conversion devices. These devices also have the potential to enable portable power generation, for example, to run small sensors in remote locations.
Currently, most thermoelectric devices rely on the longitudinal thermoelectric effect in which electricity ...
International labor migration plays a vital role in supporting families across low- and middle-income countries, often providing a critical source of income for families back home. However, when mothers migrate abroad for work, young children may be left without steady parental care during important developmental stages. While this concern is widely discussed, there has been limited real-world evidence showing how policies that restrict maternal migration affect children’s outcomes.
A new study made available online ...
This winter’s brutal flu season isn’t over, and COVID-19 cases have risen recently too. But a new poll taken in recent weeks shows that vaccination against both viruses lags among people 50 and over, and the national survey reveals key reasons why.
In all, the University of Michigan National Poll on Healthy Aging shows, 42% of people over 50 haven’t gotten either flu or COVID-19 vaccines in the past six months, though 29% have gotten both and 27% have gotten just the updated flu shot.
The poll also asked about COVID-19 vaccination since it became available in 2021: 49% of people over 50 said ...
For a long time, most scientists believed that early human hunter-gatherer societies were mostly equal, with little hierarchy or leadership, and that strong inequalities only emerged later with farming and complex societies.
However, new research out of Arizona State University is challenging this. Archaeological finds, ethnographic studies and now psychological research suggest that inequality in influence — who people listen to, copy, and follow — may have been part of human societies deep into our evolutionary past.
“At some point in our past, humans became reliant on culture,” ...
People from the Outer Hebrides and north-west Ireland have the highest risk of developing a genetic disease that causes a dangerous build-up of iron in the body, a study suggests.
The study marks the first time the genetic risk for haemochromatosis – also known as the ‘Celtic curse’ – has been mapped across the UK and Ireland, despite a high incidence of the condition among Scottish and Irish populations.
Targeting genetic screening for the condition to priority areas could help identify at-risk individuals earlier and avoid future health ...
Exploring Earth’s deep interior is a far bigger challenge than exploring the solar system. While we have travelled 25 billion km into space, the deepest we have ever gone below our feet is just over 12 km.
Consequently, little is known about the conditions at the base of the mantle and the top of the core – the most significant interface in the Earth’s interior and the region where new research has now uncovered exciting magnetic activity.
In a study published in Nature Geoscience, research led by the University of Liverpool ...
Sexual dysfunction is a reality for many women, but the subject remains taboo. A large percentage of women remain untreated, a problem that is exacerbated by the shortage of treatment options for female sexual dysfunction. A research team from GAIA in Hamburg, in cooperation with the Institute for Sexual, Psycho- and Trauma Therapy in Munich, the University of Lübeck, and the Medical School Hamburg, has now investigated the digital therapy “mylovia” The results of the randomized controlled trial (RCT) were published today in the peer-reviewed journal npj Digital Medicine and show a statistically significant and clinically relevant effect of mylovia.
mylovia ...
PHILADELPHIA — (TUESDAY, FEB. 3, 2026) — Scientists at The Wistar Institute have developed an HIV vaccine candidate that achieves something never before observed in the field: inducing neutralizing antibodies against HIV after a single immunization in nonhuman primates. The innovative approach, published in Nature Immunology, could significantly shorten and simplify HIV vaccination protocols, making them more accessible worldwide.
The research, led by Amelia Escolano, Ph.D., assistant professor in Wistar’s Vaccine and Immunotherapy Center and the senior author of the study, ...
Medical artificial intelligence is a hugely appealing concept. In theory, models can analyze vast amounts of information, recognize subtle patterns in data, and are never too tired or busy to provide a response. However, although thousands of these models have been and continue to be developed in academia and industry, very few of them have successfully transitioned into real-world clinical settings.
Marinka Zitnik, associate professor of biomedical informatics in the Blavatnik Institute at Harvard Medical ...
